Highly Mutated BA.3.2 'Cicada' COVID Variant Spreads in US, Raises Immunity Concerns
A new, highly mutated COVID-19 variant, officially designated BA.3.2 and nicknamed 'Cicada,' is spreading across at least 25 US states and over 20 other countries. First detected in South Africa in November 2024, it exhibits significant immune escape characteristics, raising concerns about vaccine effectiveness, though current data suggests it doesn't cause more severe illness. Health authorities globally are closely monitoring its evolution and impact.
Key Highlights
- BA.3.2 'Cicada' variant detected in over 25 US states and 20+ countries.
- Variant carries 70-75 spike protein mutations, indicating high genetic divergence.
- Shows 'immune escape characteristics', potentially reducing protection from prior infection or vaccination.
- Symptoms are similar to Omicron, with severe sore throat commonly reported.
- No current evidence suggests BA.3.2 causes more severe illness.
- WHO classifies BA.3.2 as a 'variant under monitoring,' emphasizing ongoing surveillance.
A new, highly mutated lineage of SARS-CoV-2, officially known as BA.3.2 and colloquially dubbed 'Cicada,' is currently under intense scrutiny by health authorities worldwide as it spreads across the United States and numerous other countries. This variant first emerged from a respiratory sample in South Africa in November 2024 and gained more noticeable traction in 2025, leading some researchers to nickname it 'Cicada' due to its long period of 'dormancy' before appearing on the global stage.
The BA.3.2 variant is characterized by an exceptionally high number of mutations, carrying approximately 70 to 75 genetic changes in its spike protein, which is significantly more than previous dominant strains like the JN.1 lineage. These extensive mutations are particularly concerning because they are concentrated in the spike protein, the part of the virus targeted by most vaccines and natural immune responses. As a result, scientists have identified that BA.3.2 exhibits 'immune escape characteristics,' meaning it has the potential to partially evade antibodies generated by prior infections or existing COVID-19 vaccines.
The variant's global footprint is expanding rapidly. As of February 11, 2026, BA.3.2 had been reported by at least 23 countries, and its presence has been detected across at least 25 to 29 US states, including California, Connecticut, Florida, Hawaii, Idaho, Illinois, Louisiana, Maine, Michigan, Maryland, Massachusetts, Missouri, New Hampshire, New Jersey, Nevada, New York, Ohio, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Vermont, Virginia, and Wyoming. Detections in the US initially occurred through traveler-based genomic surveillance in June 2025 and subsequently through wastewater monitoring, which has proven to be an effective early warning system, often identifying the variant weeks before clinical cases.
Despite its spread, the overall prevalence of BA.3.2 in the United States remains relatively low, accounting for about 0.19% to 0.55% of total genetic sequences analyzed in national surveillance as of early to mid-March 2026. However, in some European countries like Denmark, Germany, and the Netherlands, BA.3.2 detections increased to about 30% of sequences between November 2025 and January 2026, and in some areas, it reached up to 40% prevalence. The World Health Organization (WHO) has classified BA.3.2 as a 'variant under monitoring,' emphasizing the need for continued genomic surveillance to track its evolution and potential public health impact.
Regarding symptoms, individuals infected with the BA.3.2 variant appear to experience symptoms largely similar to those of previous Omicron strains. A notably common symptom reported is a severe sore throat, alongside other typical COVID-19 indicators such as fever or chills, cough, fatigue, headache, muscle aches, congestion or runny nose, and sometimes loss of taste or smell, nausea, vomiting, or diarrhea. Crucially, current data does not suggest that BA.3.2 causes more severe illness than other circulating variants. While some reports initially highlighted the variant's potential to trigger severe respiratory symptoms, medical experts and organizations like the CDC have found no evidence of increased disease severity thus far.
The immune escape potential of BA.3.2 is a primary concern for public health officials. Laboratory studies indicate that the 2025–2026 LP.8.1-adapted mRNA COVID-19 vaccine, designed to target JN.1 lineage viruses, showed the lowest antibody neutralization against BA.3.2 among several variants tested. This suggests that while current vaccines are expected to continue offering protection against severe disease and death, their effectiveness against infection from BA.3.2 might be reduced. However, real-world data on vaccine performance against this specific variant is still being collected and is crucial for a comprehensive understanding.
For an audience in India, it's important to note that BA.3.2 has not been widely reported in the country yet. However, given its spread to over 20 countries, including several in Europe and Africa, Indian health officials are maintaining vigilance. International travel remains a primary pathway for variant introduction, making robust airport surveillance and genomic tracking vital. India's extensive experience with previous COVID-19 waves and its advanced vaccination infrastructure position it to respond effectively, though continued preparedness is essential. The trajectory of BA.3.2 remains uncertain, but experts suggest it could drive a summer COVID surge in the US and potentially become a dominant strain, though this is not a certainty.
Frequently Asked Questions
What is the new COVID variant BA.3.2, also known as 'Cicada'?
BA.3.2, nicknamed 'Cicada,' is a highly mutated Omicron subvariant of SARS-CoV-2. It was first detected in South Africa in November 2024 and is characterized by 70-75 mutations in its spike protein, making it genetically distinct from previous dominant strains.
Where has the BA.3.2 'Cicada' variant been detected?
The 'Cicada' variant has been detected in over 20 countries globally, including at least 25 to 29 states in the United States, through a combination of traveler surveillance, clinical samples, and wastewater monitoring.
Does the BA.3.2 variant evade existing immunity or vaccines?
Yes, BA.3.2 exhibits 'immune escape characteristics' due to its numerous mutations, which may partially reduce the protection offered by prior infections or current COVID-19 vaccines against infection. However, the World Health Organization and other experts anticipate that vaccines will still provide protection against severe disease and death.
What are the symptoms of the 'Cicada' variant?
Symptoms of the BA.3.2 variant are generally similar to those of other Omicron strains, commonly including a severe sore throat, fever or chills, cough, fatigue, headache, muscle aches, and congestion or runny nose. There is currently no evidence that it causes more severe illness.
Should people in India be concerned about the BA.3.2 variant?
While BA.3.2 has not been widely reported in India, its presence in over 20 countries warrants vigilance. Indian health officials are monitoring the situation, and continued surveillance, particularly of international travelers, is crucial for early detection and response, leveraging India's existing preparedness for COVID-19.